BR112017027770A2 - composições e métodos para modular infecção viral - Google Patents

composições e métodos para modular infecção viral

Info

Publication number
BR112017027770A2
BR112017027770A2 BR112017027770A BR112017027770A BR112017027770A2 BR 112017027770 A2 BR112017027770 A2 BR 112017027770A2 BR 112017027770 A BR112017027770 A BR 112017027770A BR 112017027770 A BR112017027770 A BR 112017027770A BR 112017027770 A2 BR112017027770 A2 BR 112017027770A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
viral infection
modulating viral
modulating
Prior art date
Application number
BR112017027770A
Other languages
English (en)
Inventor
U Gack Michaela
K Chan Ying
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of BR112017027770A2 publication Critical patent/BR112017027770A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112017027770A 2015-06-22 2016-06-21 composições e métodos para modular infecção viral BR112017027770A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562183018P 2015-06-22 2015-06-22
US201662295635P 2016-02-16 2016-02-16
PCT/US2016/038501 WO2016209805A1 (en) 2015-06-22 2016-06-21 Compositions and methods for modulating viral infection

Publications (1)

Publication Number Publication Date
BR112017027770A2 true BR112017027770A2 (pt) 2018-09-11

Family

ID=57586686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027770A BR112017027770A2 (pt) 2015-06-22 2016-06-21 composições e métodos para modular infecção viral

Country Status (5)

Country Link
US (1) US20180185467A1 (pt)
EP (1) EP3310382A4 (pt)
CN (1) CN108472353A (pt)
BR (1) BR112017027770A2 (pt)
WO (1) WO2016209805A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018132658A1 (en) * 2017-01-13 2018-07-19 Sestan Nenad Oncolytic viruses and methods of use
BR112020008652A2 (pt) 2017-11-03 2020-11-10 Takeda Vaccines, Inc. vacinas e composições imunogênicas contra zika e métodos de uso das mesmas
SG11202004234SA (en) * 2017-11-09 2020-06-29 Pasteur Institut A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
CN107828744A (zh) * 2017-11-10 2018-03-23 山东农业大学 利用蚊源c6/36细胞系增殖培养鸭坦布苏病毒的方法
AU2018375173B2 (en) 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
US11491217B2 (en) 2017-12-06 2022-11-08 Emory University Chimeric viruses encoding mutant zika virus envelope glycoproteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080152633A1 (en) * 2005-02-16 2008-06-26 The University Of Queensland Flavivirus Replicon Constructs for Tumor Therapy
WO2012065105A2 (en) * 2010-11-12 2012-05-18 Thomas Monath Chimeric flavivirus vaccines

Also Published As

Publication number Publication date
CN108472353A (zh) 2018-08-31
WO2016209805A1 (en) 2016-12-29
US20180185467A1 (en) 2018-07-05
EP3310382A4 (en) 2019-01-02
EP3310382A1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
DK3400291T3 (da) Manipuleret virus
DK3393510T3 (da) Zikavirusvaccine
DK3380108T3 (da) Udformede bakterielle sammensætninger
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3172319T3 (da) Coronavirus
KR20180084891A (ko) 구조 조성물 및 방법
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3416996T3 (da) Hærdelig sammensætning
DK3274430T3 (da) Mikroalgesammensætninger og deres anvendelser
DK3334726T3 (da) Plinabulinsammensætninger
BR112017027770A2 (pt) composições e métodos para modular infecção viral
MA42692A (fr) Compositions biopharmaceutiques
DK3277802T3 (da) Aseptisk oprensningsfremgangsmåde for virusser
DK3250182T3 (da) Dispergible sammensætninger
DK3129007T3 (da) Vaccinesammensætninger
DK3316856T3 (da) Blandede formuleringer
DK3250550T3 (da) Sammensætninger og fremgangsmåder til virussensibilisering
DK3148517T3 (da) Sammensætninger og fremgangsmåder til fremme af knogledannelse
DK3280447T3 (da) Farmaceutiske formuleringer
DK3166960T3 (da) Lav-substituerede polymyxiner og sammensætninger deraf
CL2016001249S1 (es) Conjunto soplador
DK3288933T3 (da) Oxindolforbindelser og farmaceutiske sammensætninger deraf

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing